{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-26-000062","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2026-08-04T20:05:24+00:00","discovered_at":"2026-08-04T20:07:00.223737+00:00","generated_at":"2026-08-04T20:08:14.203101+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Travere Q2: FILSPARI sales +96% to $141M; FSGS launch drives 2,012 PSFs; net loss $34.8M","bullets":["U.S. net product sales $161.4M in Q2 2026, up from $94.8M; FILSPARI sales $141.1M (+96% YoY).","Net loss $34.8M ($0.37/share) vs $12.8M loss in Q2 2025; non-GAAP net loss $9.0M ($0.10/share).","Cash $489.2M; issued $525M of 0.5% convertible notes due 2032, repurchased $221M of 2029 notes.","In-licensed civorebrutinib from Everest Medicines for $112.5M upfront; plans to study in pMN, FSGS, MCD.","Phase 3 HARMONY for pegtibatinase in HCU enrolling; topline data expected 2H 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-26-000062","json":"https://secwatch.observer/filing/0001438533-26-000062.json","markdown":"https://secwatch.observer/filing/0001438533-26-000062.md","text":"https://secwatch.observer/filing/0001438533-26-000062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000062/0001438533-26-000062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000062/tvtx-20260804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T20:08:14.203101+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}